UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 61 filers reported holding UNIQURE NV in Q4 2017. The put-call ratio across all filers is 0.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $268,000 | -71.4% | 7,100 | -82.2% | 0.02% | -73.3% |
| Q1 2018 | $937,000 | -39.6% | 39,900 | -75.3% | 0.06% | -27.7% |
| Q3 2017 | $1,551,000 | -3.7% | 161,600 | -37.9% | 0.08% | -16.2% |
| Q2 2017 | $1,610,000 | -9.3% | 260,100 | -15.3% | 0.10% | -11.6% |
| Q1 2017 | $1,775,000 | -10.8% | 307,200 | -13.6% | 0.11% | -31.7% |
| Q4 2016 | $1,991,000 | -6.7% | 355,700 | +27.4% | 0.16% | -5.2% |
| Q3 2016 | $2,135,000 | -23.8% | 279,100 | -26.6% | 0.17% | -34.0% |
| Q2 2016 | $2,803,000 | -20.3% | 380,400 | +28.5% | 0.26% | -26.2% |
| Q1 2016 | $3,516,000 | -8.0% | 296,000 | +28.1% | 0.36% | -27.1% |
| Q4 2015 | $3,822,000 | +513.5% | 231,100 | +657.7% | 0.49% | +501.2% |
| Q3 2015 | $623,000 | -55.4% | 30,500 | -41.1% | 0.08% | -58.5% |
| Q2 2015 | $1,398,000 | +11.7% | 51,800 | 0.0% | 0.20% | +11.4% |
| Q1 2015 | $1,252,000 | +406.9% | 51,800 | +210.2% | 0.18% | +316.7% |
| Q4 2014 | $247,000 | – | 16,700 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
| Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
| 683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
| PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
| Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
| Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
| Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
| Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
| Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |